Robert Lobel, MD
Urogynecology and Reconstructive Pelvic Surgery · Albany, NYNPI 1659332765
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 448 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 65.7% of it on its own, with 16 other manufacturers making up the rest.
Across 448 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Sumitomo Pharma America, Inc.$663
- Astellas Pharma US Inc$465
- AbbVie$314
- Urovant Sciences Inc$259
- Pfizer$174
- plus $507 from 11 others
Across 71 payments — averaging $6301.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$447K
What the payments were for
- Food & beverage$6,80498%
- Education$1452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 322 | $4,567 |
| Sumitomo Pharma America, Inc. | 34 | $663 |
| Astellas Pharma US Inc | 24 | $465 |
| AbbVie(2 entities) | 17 | $314 |
| Urovant Sciences Inc | 11 | $259 |
| Pfizer | 17 | $174 |
| Boston Scientific | 5 | $122 |
| Axonics, Inc. | 3 | $97 |
| Coloplast | 4 | $78 |
| Integra Lifesciences Corporation | 2 | $70 |
| Therapeuticsmd, Inc. | 3 | $39 |
| AMAG Pharmaceuticals, Inc. | 1 | $22 |
| 180 Medical, Inc. | 1 | $21 |
| Myovant Sciences Inc. | 1 | $17 |
| Rochester Medical Corporation | 1 | $16 |
| Dentsply IH Inc. | 1 | $12 |
| Hollister Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$262
How this compares
$6,950 in reported general payments places this provider in the 75th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
See all urogynecology and reconstructive pelvic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 491 | $539,438 |
| GemtesaVibegron | 382 | $436,603 |
| PremarinEstrogens, Conjugated | 112 | $51,309 |
| Mirabegron ErMirabegron | 41 | $24,645 |
| EliquisApixaban | 19 | $22,360 |
| Trimethoprim | 241 | $22,096 |
| XareltoRivaroxaban | 15 | $17,997 |
| Solifenacin Succinate | 122 | $17,229 |
| VeozahFezolinetant | 13 | $16,358 |
| Estradiol | 182 | $15,581 |
| EstringEstradiol | 28 | $15,141 |
| NitrofurantoinNitrofurantoin Macrocrystal | 201 | $11,540 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 68 | $8,015 |
| Fosfomycin Tromethamine | 50 | $6,829 |
| Trospium Chloride | 84 | $6,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq, Veozah | $465 | $555,796504 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $663 | $436,603382 claims |
| PfizerPremarin, Eliquis, Estring | $174 | $88,810159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
Other urogynecology and reconstructive pelvic surgery in Albany
- Jason KimStony Brook$346K
- Dara ShalomGreat Neck$94K
- Harvey WinklerGreat Neck$81K
- Robert MoldwinNew Hyde Park$35K
- Nitya AbrahamBronx$24K
- Cornelius VerhoestPoughkeepsie$21K
- Abeer EddibCheektowaga$19K
- Wai LeeNew Hyde Park$17K
- Doreen ChungNew Hyde Park$14K
- Jennifer HillRiverhead$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.